Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-29 21:28:39 - browse：7597

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Why the Crimean Bridge is key to Russia's war in Ukraine

entertainment

WSS

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

DOJ, FTC to increase scrutiny of all types of health care mergers

Childbirth

Akili, maker of video game for ADHD, to be acquired for 34 million

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

What does generative AI mean for health care? We asked experts

What will save rural psychiatry services? Higher Medicaid payments

DIEP, the 'gold standard' of breast reconstruction, is under threat

Do more moles mean more problems? Not so, says new study

ChatGPT in medicine: STAT answers readers' burning questions

Insmed lung disease drug hits target in key Phase 3 trial

At least 13 dead in Texas as scorching temps continue

'Reaching a detente': STAT's Helen Branswell on covering Covid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Antibiotic resistance nearly killed me, so I'm raising awareness of it

leisure time

iTeos Therapeutics debuts first data on TIGIT

Biohaven protein

Latest bird flu infection made farmworker sicker than earlier cases

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Addiction doctors spar with methadone clinics over legislation

knowledge

entertainment

knowledge

hotspot